Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 2

Sponsor Class

OTHER 10NIH 2INDUSTRY 2OTHER_GOV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 132Lymphoid 82Other hematologic neoplasm 23Myeloid 5Genitourinary 4Dermatologic 3Tumor-Agnostic 2Thoracic 2Gynecologic 2Gastrointestinal 2Sarcoma 1Other solid neoplasm 1Head & Neck 1Classical hematology 1

Conditions

Pancreatic Neoplasms 1Colorectal Neoplasms 1

Interventions

Gemcitabine 301Fluorouracil 295Oxaliplatin 268Bevacizumab 268Capecitabine 233Leucovorin 227pembrolizumab 215Irinotecan 183Cisplatin 142Cetuximab 142Nivolumab 130Paclitaxel 116130-nm albumin-bound paclitaxel 116Sorafenib 86Albumin-Bound Paclitaxel 75regorafenib 64atezolizumab 64Docetaxel 64Folfox protocol 62IFL protocol 61Trastuzumab 54Panitumumab 47durvalumab 46Ramucirumab 43Injections 42Sunitinib 41Drug Therapy 41Carboplatin 40trifluridine tipiracil drug combination 38lenvatinib 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Lenalidomide × Gastrointestinal × Clear all
NCT01032291 2013-05-21

A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer

Celgene

Phase 2 Terminated
51 enrolled 12 charts
Gastrointestinal

Colorectal Neoplasms

NCT00179751 2005-11-07

A Phase I/II Study of Lenalidomide in Combination With Gemcitabine in Patients With Untreated Advanced Carcinoma of the Pancreas

Celgene

Phase 1/2 Terminated
50 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡